Biodexa Pharmaceuticals reported net income of -$2.35M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Dec 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2013 | Dec2014 | Dec2015 | Jun2016 | Dec2016 | Jun2017 | Dec2017 | Jun2018 | Dec2018 | Jun2019 | Dec2019 | Jun2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | ||||||||||||||||||||||||
| Revenue | 7.24M | 5.15M | 5.00M | |||||||||||||||||||||
| Interest income | ||||||||||||||||||||||||
| Interest Income - Total | -0.09M | |||||||||||||||||||||||
| Interest expenses | ||||||||||||||||||||||||
| Interest ExpensesInterest Expense | -0.73M | -0.08M | -0.76M | -0.12M | -0.57M | -0.03M | -0.03M | -0.06M | -0.18M | -0.18M | -0.08M | |||||||||||||
| Interest Income - Net | -1.57M | |||||||||||||||||||||||
| Operating Items | ||||||||||||||||||||||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | -1.26M | -0.01M | -1.30M | |||||||||||||||||||||
| Research & DevelopmentR&D | -10.99M | -0.47M | -12.04M | -10.08M | -8.01M | -2.83M | -2.82M | -2.81M | -2.22M | -2.21M | -3.91M | |||||||||||||
| Selling, General & AdministrativeSG&A | -6.17M | -1.16M | -5.65M | -4.94M | -6.54M | -2.17M | -2.87M | -2.61M | -3.17M | -3.16M | -2.33M | |||||||||||||
| Restructuring CostsRestructuring | ||||||||||||||||||||||||
| Other Operating ExpensesOther Opex | 0.01M | 0.01M | ||||||||||||||||||||||
| Operating ExpensesOpex | -18.42M | -1.64M | -19.00M | -15.02M | -14.55M | -5.00M | -5.68M | -5.42M | -5.39M | -5.38M | -6.24M | |||||||||||||
| Operating IncomeOp. Inc | -20.48M | -6.19M | -15.20M | -14.55M | -30.42M | -4.43M | -5.31M | -5.42M | -5.36M | -5.34M | -5.65M | |||||||||||||
| EBIT | -20.48M | -6.19M | -15.20M | -14.55M | -30.42M | -4.43M | -5.31M | -5.42M | -5.36M | -5.34M | -5.65M | |||||||||||||
| Non-operating items | ||||||||||||||||||||||||
| Non Operating Interest Expenses | -0.73M | -0.08M | -0.76M | -0.12M | -0.57M | -0.03M | -0.03M | -0.06M | -0.18M | -0.18M | -0.08M | |||||||||||||
| Goodwill impairment chargesGoodwill Impair. | -1.86M | -1.99M | -1.93M | -16.33M | ||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.47M | 1.08M | 0.24M | ||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.04M | |||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||
| EBT | -21.21M | -6.19M | -15.96M | -14.04M | -30.99M | -3.99M | -4.83M | -4.41M | -5.30M | -5.28M | -2.41M | |||||||||||||
| Tax ProvisionsTaxes | 2.53M | 0.40M | 0.16M | 0.22M | -0.06M | |||||||||||||||||||
| Profit After TaxPAT | -23.74M | -6.19M | -15.96M | -14.04M | -30.99M | -4.38M | -4.83M | -4.57M | -5.30M | -5.50M | -2.35M | |||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -12.89M | -5.79M | -13.34M | -11.75M | -29.30M | -7.36M | -4.38M | -4.83M | -4.57M | -5.30M | -5.50M | -2.35M | ||||||||||||
| Income from Discontinued OperationsIncome (Discontinued) | -36.45M | -27.79M | -6.00M | -1.22M | ||||||||||||||||||||
| Consolidated Net IncomeConsol Net Inc. | -18.69M | -6.19M | -19.34M | -12.97M | -29.30M | -7.36M | -4.38M | -4.83M | -4.57M | -5.30M | -5.50M | -2.35M | ||||||||||||
| Income towards Parent CompanyParent Net Inc | -18.69M | -6.19M | -19.34M | -12.97M | -29.30M | -7.36M | -3.59M | -4.46M | -4.25M | -5.08M | -5.06M | -2.47M | ||||||||||||
| Net Income towards Common StockholdersNet Income | -18.69M | -6.19M | -19.34M | -12.97M | -29.30M | -7.36M | -3.59M | -4.46M | -4.25M | -5.08M | -5.06M | -2.47M | ||||||||||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -51.80 | -17.16 | -53.61 | -14.15 | -68.39 | -9.14 | -3.63 | -4.52 | -0.07 | -0.08 | -0.08 | -0.04 | ||||||||||||
| Shares Outstanding | 0.36M | 0.36M | 0.36M | 0.36M | 0.36M | 0.36M | 0.92M | 0.92M | 0.43M | 0.43M | 0.81M | 0.81M | 0.99M | 0.99M | 63.17M | 63.17M | 63.17M | 63.17M | 63.17M | 63.17M | ||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.36M | 0.92M | 0.43M | 0.81M | 1.08M | 63.17M |
Pull Biodexa Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=BDRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "BDRX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=BDRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();